Medicare Part B may help with the costs of Keytruda. Outpatient facilities usually administer the drug intravenously, and Part B covers outpatient services. The generic name for Keytruda is ...

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 ...

The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions of dollars in the coming years. Several factors ...

Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.

Manufacturing companies are particularly attentive to drugs designated as breakthrough therapies due to the accelerated market access and higher returns on investment. Breakthrough therapy drugs often ...

Novartis has entered into an exclusive licence agreement with Legend Biotech for global rights to a selection of CAR-T cell therapies targeting DLL3, with the deal potentially worth over $1bn. Under ...

Isas were launched by Gordon Brown in 1999. Cash versions are the more popular than stocks and shares ones, with some £421billion held in cash Isas out of the total £726billion held in Isas in ...